{"id":3552,"date":"2024-06-07T13:16:15","date_gmt":"2024-06-07T10:16:15","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3552"},"modified":"2024-06-07T13:16:16","modified_gmt":"2024-06-07T10:16:16","slug":"gilead-turkiyeden-bolge-yonetimine-atama","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3552","title":{"rendered":"Gilead T\u00fcrkiye\u2019den B\u00f6lge Y\u00f6netimine Atama\u00a0"},"content":{"rendered":"\n<p><em><strong>D\u00fcnyada 35\u2019ten fazla \u00fclkede faaliyet g\u00f6steren bilim \u015firketi Gilead, global y\u00f6netim ekibine T\u00fcrkiye\u2019den y\u00f6netici transfer etmeye devam ediyor. Gilead T\u00fcrkiye HIV \u0130\u015f Birimi Direkt\u00f6r\u00fc G\u00f6zde \u00dcnverdi Arslan, Gilead Orta Do\u011fu Sat\u0131\u015f ve Pazarlama K\u0131demli Direkt\u00f6rl\u00fc\u011f\u00fc\u2019ne getirildi. B\u00f6ylece Gilead\u2019\u0131n global y\u00f6netime transfer edilen y\u00f6netici say\u0131s\u0131 son 5 y\u0131lda 17\u2019ye ula\u015ft\u0131.<\/strong><\/em><\/p>\n\n\n\n<p>Yapt\u0131\u011f\u0131 yerel yat\u0131r\u0131mlarla global \u00f6l\u00e7ekte yenilik\u00e7i tedavileri T\u00fcrkiye\u2019de \u00fcreten ABD merkezli Gilead, T\u00fcrkiye\u2019den d\u00fcnyaya y\u00f6netici ihra\u00e7 ediyor. Gilead T\u00fcrkiye HIV \u0130\u015f Birimi Direkt\u00f6r\u00fc G\u00f6zde \u00dcnverdi Arslan, Gilead Orta Do\u011fu Sat\u0131\u015f ve Pazarlama K\u0131demli Direkt\u00f6rl\u00fc\u011f\u00fc\u2019ne atand\u0131.&nbsp;<\/p>\n\n\n\n<p>Gilead T\u00fcrkiye\u2019ye iki y\u0131l \u00f6nce HIV \u0130\u015f Birimi Direkt\u00f6r\u00fc olarak kat\u0131lan Arslan, yeni g\u00f6revinde Gilead\u2019\u0131n Orta Do\u011fu&#8217;daki HIV, viral hepatit, anti-fungal ve COVID-19 alanlar\u0131ndaki operasyonlar\u0131n\u0131n y\u00f6netimine ve i\u015f geli\u015ftirme faaliyetlerine liderlik edecek. Arslan, yeni g\u00f6revinde Gilead\u2019\u0131n Orta Do\u011fu\u2019da faaliyet g\u00f6sterdi\u011fi 12 \u00fclkeden sorumlu olacak.<\/p>\n\n\n\n<p>Bo\u011fazi\u00e7i \u00dcniversitesi\u2019nden Kimya M\u00fchendisli\u011fi lisans ve Executive MBA y\u00fcksek lisans derecesine sahip olan Arslan, \u00e7al\u0131\u015fma hayat\u0131na ba\u015flad\u0131ktan sonra Bayer, AstraZeneca, Novartis ve Roche gibi ila\u00e7 sekt\u00f6r\u00fcn\u00fcn \u00f6nde gelen \u015firketlerinde, \u00fclke ve b\u00f6lge organizasyonlar\u0131nda, sat\u0131\u015f ve pazarlama, stratejik planlama, i\u015f operasyonlar\u0131 ve pazar eri\u015fimi alanlar\u0131nda farkl\u0131 liderlik g\u00f6revleri ald\u0131. Orta ve Do\u011fu Avrupa&#8217;da b\u00f6lgesel rollerde g\u00f6rev ald\u0131.<\/p>\n\n\n\n<p>Gilead, ya\u015fam\u0131 tehdit eden hastal\u0131klara kar\u015f\u0131 yenilik\u00e7i tedavi y\u00f6ntemleri geli\u015ftiriyor. 2007 y\u0131l\u0131ndan bu yana T\u00fcrkiye\u2019de faaliyet g\u00f6steren Gilead,&nbsp;60 milyon dolarl\u0131k yerelle\u015fme yat\u0131r\u0131m\u0131yla portf\u00f6y\u00fcndeki en yeni Hepatit B tedavisini ve en yenilik\u00e7i HIV ila\u00e7lar\u0131n\u0131 T\u00fcrkiye\u2019de \u00fcretmeye ba\u015flad\u0131. Gilead, klinik \u00e7al\u0131\u015fmalarla birlikte \u00fclkemizde son 6 y\u0131lda 7.2 milyon dolar de\u011ferinde Ar-Ge deste\u011fi sa\u011flad\u0131. T\u00fcrkiye, yerel \u00fcretim yat\u0131r\u0131mlar\u0131yla Almanya, Kanada ve \u0130rlanda\u2019dan sonra Gilead\u2019\u0131n yenilik\u00e7i tedavilerini \u00fcretti\u011fi 4. \u00fcretim \u00fclkesi oldu.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00fcnyada 35\u2019ten fazla \u00fclkede faaliyet g\u00f6steren bilim \u015firketi Gilead, global y\u00f6netim ekibine T\u00fcrkiye\u2019den y\u00f6netici transfer etmeye devam ediyor. Gilead T\u00fcrkiye HIV \u0130\u015f Birimi Direkt\u00f6r\u00fc G\u00f6zde \u00dcnverdi Arslan, Gilead Orta Do\u011fu Sat\u0131\u015f ve Pazarlama K\u0131demli Direkt\u00f6rl\u00fc\u011f\u00fc\u2019ne getirildi. B\u00f6ylece Gilead\u2019\u0131n global y\u00f6netime transfer edilen y\u00f6netici say\u0131s\u0131 son 5 y\u0131lda 17\u2019ye ula\u015ft\u0131.<\/p>\n","protected":false},"author":1,"featured_media":3553,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3552"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3552"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3552\/revisions"}],"predecessor-version":[{"id":3554,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3552\/revisions\/3554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3553"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}